Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
Information source: National Taiwan University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Liver Disease
Intervention: morphine and glucagon (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: National Taiwan University Hospital Official(s) and/or principal investigator(s):
Hon-Man Liu, MD, Study Chair, Affiliation: National Taiwan University Hospital
Overall contact:
Yuan-Heng Mo, MD, Email: jamesmyh@ha.mc.ntu.edu.tw
Summary
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile
secretion and dilatation of bile duct. We conduct this randomized double blinded study to
evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
Primary outcome: MRCP visibility
Detailed description:
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile
secretion and dilatation of bile duct. We conduct this randomized double blinded study to
evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.
Eligibility
Minimum age: 20 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- normal volunteer
- living liver donor
Exclusion Criteria:
- COPD
- chronic liver disease
- hypersensitive to glucagon
- DM
- insulinoma
- glucagonoma
- pregnancy
Locations and Contacts
Yuan-Heng Mo, MD, Email: jamesmyh@ha.mc.ntu.edu.tw
National Taiwan University Hospital, Taipei, province of Taiwan 100, Taiwan; Recruiting
Yuan-Heng Mo, MD, Email: jamesmyh@ha.mc.ntu.edu.tw
Additional Information
Starting date: September 2005
Last updated: November 25, 2005
|
